A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. - Trial NCT06298058
Access comprehensive clinical trial information for NCT06298058 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Institute Of Biological Products and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 144 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Institute Of Biological Products
Timeline & Enrollment
Phase 1
Mar 12, 2024
Jun 30, 2026
Primary Outcome
AE (Adverse Events),SAE (Serious Adverse Events),AUC (Area Under The Plasma Concentration Versus Time Curve),Cmax (Peak Plasma Concentration),Tmax (Peak Time),T ½ (Terminal elimination half-life),CL (Clearance Rate)
Summary
To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A13 and
 determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06298058
Non-Device Trial